Medical Marijuana in Connecticut: What the Evidence Actually Supports

Connecticut's Medical Marijuana Program has been active since 2012, and it remains separate from the state's recreational market for good reason — tax savings, higher possession limits, and access to product formats and potency that recreational buyers don't get. What gets less attention is a more basic question: for the conditions Connecticut recognizes, what does the research actually show?

The honest answer is that it varies a lot by condition. Some of what's on Connecticut's qualifying list is backed by real evidence. Some of it is included because a state's list of qualifying conditions is ultimately a policy decision, not strictly a reflection of trial data. I'd rather tell you which is which than let the list itself imply that every condition on it has equally strong support.

Where the evidence is genuinely strong

The most thorough evaluation of cannabis research to date came from the National Academies of Sciences, Engineering, and Medicine in 2017, which reviewed thousands of studies and graded the evidence by health outcome using a standard scale — conclusive, substantial, moderate, limited, or insufficient.¹ A handful of uses cleared the highest bar:

• Chronic pain in adults — the best-supported use in the entire report, and the reason chronic pain is Connecticut's most common qualifying pathway
• Chemotherapy-induced nausea and vomiting — supported strongly enough that two cannabinoid medications, dronabinol and nabilone, are FDA-approved prescription drugs for this specific use
• Multiple sclerosis spasticity — patient-reported spasticity symptoms improve with cannabinoid treatment across multiple good-quality trials

A 2022 systematic review commissioned by the Agency for Healthcare Research and Quality reinforced the chronic pain finding specifically, showing that high THC-to-CBD ratio products were associated with a moderate improvement in pain severity, alongside an increased risk of sedation and dizziness.² None of this means cannabis works as well as people sometimes expect, or that it works the same way for everyone — but for these three uses, the research base is genuinely solid.

Where the evidence is moderate

A step below conclusive, the NASEM report found moderate evidence that cannabis improves short-term sleep outcomes in people with disturbed sleep related to obstructive sleep apnea, fibromyalgia, chronic pain, and multiple sclerosis.¹ That's a real finding, but a narrower one than "cannabis helps you sleep" — it's specifically about sleep disruption tied to another underlying condition, over a short time frame, not sleep in general.

Where the evidence is thinner than the qualifying list implies

This is the part most sources don't say plainly. A 2025 analysis compared every state's qualifying-condition list against the NASEM evidence grades and found that only about 8% of the conditions states actually recognize meet the "substantial or conclusive" bar — and PTSD and epilepsy, two of the more commonly cited qualifying conditions nationally, were graded as having only limited or insufficient evidence in the original report, not substantial.³ Glaucoma is a longer-standing example: it's been a qualifying condition in many states for years, despite evidence suggesting cannabis's effect on eye pressure is too short-lived to meaningfully treat the disease.

I'm not pointing this out to talk anyone out of certification. States recognize conditions for reasons beyond a strict reading of one evidence report — patient-reported benefit, safety relative to alternatives like long-term opioids, and quality-of-life factors that a trial doesn't always capture. But if you're deciding whether to pursue certification for a specific condition, it's worth knowing where your condition actually falls on that spectrum rather than assuming the state's list is itself a guarantee of proven efficacy.

How Connecticut's program actually works

Connecticut recognizes more than 30 qualifying conditions, including cancer, epilepsy and seizure disorders, multiple sclerosis, Crohn's and ulcerative colitis, PTSD, fibromyalgia, complex regional pain syndrome, sickle cell disease, and chronic pain conditions refractory to other treatment, among others. Certification requires evaluation by a Connecticut-licensed physician, physician assistant, or APRN who reviews your diagnosis and history and determines whether the potential benefit of medical cannabis outweighs the risk for your specific situation — it isn't automatic, and it isn't the same conversation for every condition on the list.

Once certified, you complete your registration with the state's Department of Consumer Protection, which issues your card directly. From there, the program gives you access to product formats and potency levels the recreational market doesn't offer, without the tax that applies to recreational purchases.

What I won't do in a blog post

Dosing, product selection, and how to use cannabis alongside other medications are genuinely individual decisions that depend on your specific health history — not something responsible to generalize in an article. That's exactly what the certification visit is for.

If you're a Connecticut resident with a condition that may qualify, the Connecticut Medical Marijuana Card page has current pricing, the full qualifying conditions list, and how the telehealth certification visit works.

Sources

1. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
2. McDonagh MS, Selph SS, Buckley DI, et al. Cannabis-based products for chronic pain: a systematic review. Ann Intern Med. 2022;175(8):1143–1153.
3. Stains EL, Kennalley AL, Tian M, Boehnke KF, Kraus CK, Piper BJ. Medical cannabis in the United States: comparing 2017 and 2024 state qualifying conditions to the 2017 National Academies of Sciences report. Mayo Clin Proc Innov Qual Outcomes. 2025;9(2):100590.